Manipal Health ₹9000 crore IPO 2026 | Should You Apply?

Rising insurance penetration, an ageing population and growing demand for complex treatment are steadily moving patients toward organised hospital chains.

Manipal Health Enterprises sits comfortably at the centre of that shift, running 49 hospitals with 13,037 licensed beds across 14 states and union territories, the largest private hospital network in India by bed capacity. 

It is now coming to market with a ₹9,275.22 crore IPO at ₹560 to ₹590 per share, valuing the company at about ₹77,606 crore.

At roughly 85 times FY26 earnings, what does the business need to deliver for that price to make sense?

Manipal Health Enterprises runs multispecialty hospitals that cover everything from outpatient consultations to advanced care such as organ transplants, cardiac surgery, oncology and neurosurgery.

These treatments generate higher revenue per patient, but they also require specialised equipment and experienced doctors. That is where the group has focused much of its investment.

In FY26, the network treated 7.63 million patients and had 11,064 doctors across its hospitals.

It is also the only private hospital chain in India that leads three major metro markets by bed capacity: Bengaluru, Kolkata and Pune. It also holds leading positions in Karnataka, the Maharashtra and Goa region, and eastern India.

The business earns revenue from three main payor groups.

Cash-paying and privately insured patients generate the highest realisation and stand to benefit as insurance coverage expands.

Corporate tie-ups bring steady patient volumes, although rates are usually negotiated in advance.

Government schemes contributed 13.80 percent of revenue in FY26, up from 11.04 percent in FY24.

 These schemes support volumes, but the tariffs are lower than commercial rates.

By specialty, a large share of revenue comes from what the company calls CONGO R. This includes cardiac sciences, oncology, neurosciences, gastro sciences, orthopaedics and renal sciences.

Together, these specialties contributed 64.30 percent of gross inpatient revenue.

Karnataka remained the largest market, contributing 46.40 percent of revenue. However, this was down from 59.98 percent two years earlier as the network expanded into other regions.

This is largely a fresh issue rather than a promoter exit. 

Of the ₹9,275.22 crore raised, ₹8,000 crore is new capital for the company and ₹1,275.22 crore goes to selling shareholders including Temasek and TPG entities, so roughly 86 percent of the money stays with the business.

Interestingly, 2 details changed between the draft prospectus in March and the final offer.

The offer for sale was reduced from 4.32 crore shares to 2.16 crore, so existing holders are selling less than first proposed, and the retail allocation moved from 35 percent to 10 percent with institutions taking 75 percent. 

• Valuation: The price builds in the debt repayment, improving occupancy and a margin recovery, so there is limited cushion if these take longer.

   

• Occupancy and utilisation: Manipal has 13,037 licensed beds and 6,227 operational, so filling that capacity is central to the near term earnings path.

   

• Integration: The Sahyadri acquisition closed in late 2025 and integration is still in progress. Doctor retention is usually the first indicator here.

   

• Geographic concentration: Karnataka still contributes 46.40 percent of revenue, although this has come down meaningfully.

   

• Regulatory pricing: Caps on stents, implants and devices have been introduced before and could return, with hospitals typically absorbing them.

   

• Payor mix: Government share at 13.80 percent has been rising, so part of the volume growth comes at lower realisation.
   

Manipal Health offers exposure to India's largest hospital network at a point where reported earnings still carry acquisition related interest, depreciation and integration costs. The offer is structured so most of the money strengthens the business, and the debt repayment alone should support earnings even before operations improve.
 

The balancing point is that much of the value here is ahead rather than behind. The repayment, the occupancy recovery and the Sahyadri integration are all in progress, so FY26 reflects the investment phase rather than the payoff.
 

Investors comfortable holding through a few years of execution get a market position that is hard to find elsewhere in listed Indian healthcare. Those who prefer more evidence can watch one finance cost print and one occupancy print after listing.

What are the IPO dates for Manipal Health IPO? 
IPO opens on July 29, 2026 and closes on July 31, 2026. Allotment is expected on August 3 and listing on August 5 on the BSE and NSE.
 

What is Manipal Health IPO GMP? 
Grey market premium peaked near ₹50 on July 20 and was around ₹10 by July 28, implying a listing premium of roughly 1 to 2 percent. GMP is unofficial and moves quickly, so it is best treated as a mood check.
 

What is the lot size for retail investors? 
The minimum lot is 25 shares, requiring ₹14,750 at the upper price band of ₹590.
 

Is Manipal Health IPO a fresh issue or an OFS? 
Both. The fresh issue is ₹8,000 crore and the offer for sale ₹1,275.22 crore, so about 86 percent of proceeds go to the company.
 

Should I invest in the Manipal Health IPO? 
Scale, brand strength and a much stronger post issue balance sheet sit alongside a premium valuation and an occupancy recovery still underway. Reading the prospectus risk factors and matching the holding period to your own plan is a sensible next step.